Touro Scholar
NYMC Faculty Posters

Faculty

2-2017

Autologous Mesenchymal Stem Cell Transplantation in Male
Stress Urinary Incontinence
Benjamin Mann
New York Medical College

Keerat Kaur
New York Medical College

John Phillips
New York Medical College

Carol Eisenberg
New York Medical College, carol_eisenberg@nymc.edu

Leonard M. Eisenberg
New York Medical College, leonard_eisenberg@nymc.edu

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_posters
Part of the Urology Commons

Recommended Citation
Mann, B., Kaur, K., Phillips, J., Eisenberg, C., & Eisenberg, L. M. (2017). Autologous Mesenchymal Stem
Cell Transplantation in Male Stress Urinary Incontinence. Retrieved from https://touroscholar.touro.edu/
nymc_fac_posters/19

This Poster is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for
inclusion in NYMC Faculty Posters by an authorized administrator of Touro Scholar.For more information, please
contact touro.scholar@touro.edu.

Autologous Mesenchymal Stem Cell Transplantation in Male Stress Urinary Incontinence
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METHODS

BACKGROUND
Radical prostatectomy is the most traditional treatment for prostate cancer,
which affects one out of every seven men. One of the most common side effects of a radical
prostatectomy is stress urinary incontinence. [1] A 2010 study states that:
At 6 weeks after surgery 59% (405) of men were incontinent, defined as any pad use. At 58
weeks after surgery 22% (165) of men were incontinent. At 58 weeks incontinence was more
prevalent in men who were obese and physically inactive (59% incontinent). Physical activity
may offset some of the negative consequences of being obese because the prevalence of
incontinence at 58 weeks was similar in the obese and active (25% incontinent), and nonbese
and inactive (24% incontinent) men. The best outcomes were in men who were nonobese and
physically active (16% incontinent). Men who were not obese and were active were 26% less
likely to be incontinent than men who were obese and inactive (RR 0.74, 95% CI 0.52–1.06).
[2]
Furthermore, almost 10% of patients experience urinary incontinence permanently.
Conservative treatment for stress urinary incontinence in men consists of pelvic floor exercises.
In cases when conservative treatment is unsuccessful, “urethral bulking agents, male slings,
and the artificial urinary sphincter” can be used. Stem cells have proven to have regenerative
effects and have been looked into as a treatment for urinary incontinence in women, by using
stem cells to repopulate missing smooth muscle in the pelvic floor muscles. [3] Therefore, it is
necessary to look into stem cells as a possible treatment for male urinary incontinence.
An animal trial is a necessary step in accessing how safe an effective a possible drug can be.
Generally, it is difficult to find a mouse model that displays incontinence. Previous animal
models used to test stem cell treatments for urinary incontinence involved artificially creating
incontinence in mice.[3] In order to determine if a mouse is urinary incontinent, one can
observe the urination pattern of a mouse model in a cage. Generally, mice urinate in one or two
discriminate locations, which can be observed by placing filter paper on the bottom of the cage.
When a mouse is urinary incontinent, there would be spots on the filter paper indiscriminately.
[4] There is an animal model that is currently being used in a bladder cancer study associated
with New York Medical College and other institutions that display the indiscriminant urination
pattern, and have been determined to be an excellent model of urinary incontinence. The goal
of the summer was to determine how to consistently produce smooth muscle cells from mouse
bone marrow.
Following review of literature, Transforming Growth Factor Beta (TGF-ß) was decided to be
the cytokine of choice. It has been proven that TGF-ß can cause smooth muscle cell
differentiation through the SMAD2/SMAD3 pathway and its role in increasing the expression
of myocardin, another factor in smooth muscle differentiation. Both TGFß-1 and TGFß-3 were
investigated throughout the study. Finally, the projected to attempted to find the ideal
conditions for smooth muscle differentiation using the TGF-ß pathway.

HYPOTHESIS

RESULTS CONTINUED

Bone Marrow Derivation.
Animal protocols were approved by the Institutional Animal Care and Use Committee at New York
Medical College. Standard protocol was followed to remove the bone marrow from the mice. [5]
Following collection of bone marrow, a Ficoll Paque gradient was used to separate the cells in bone
marrow by density. The mesenchymal stem cells were collected from the gradient and resuspended in
Iscoves Modified Dublecco’s Media (IMDM) with 20% FBS at a concentration of 10^6 cell per mL of
serum in petri dishes. The cells were cultured for three weeks and were fed every three days.

Treatment
Following aspiration of IMDM/20% FBS from one 60 mL dish of MSCs, cells were resuspended with
trypsin/EDTA. Cells were then spun at 1000 RPM, 31˚C for 10 minutes, and the supernatant was
removed. The remaining pellet was placed in 4 mL of IMDM/20% FBS. 2 mL of the serum mixed with
cells were placed in one column (4 chambers) of a Lab-Tek chamber slide. TGFß-1/TGFß-3 was then
added at a concentration of 1 ng/mL. The remaining mix was then added to the other column in the LabTek chamber slide. Allow the chamber to incubate at 4 ˚C for 72-hours.

Shown is an example of a Lab-Tek Chamber slide. The
unique slide contains eight wells that can be removed after
testing to allow a quick transfer from testing to analysis.

Immunohistostaining
IMDM/20% FBS/TGFß-3 serum was removed from the chambers by aspiration. The chambers were then
washed with phosphate buffer saline (PBS), and then filled with chilled menthol. After a 15-minute
incubation period, the chambers three times using PBS. The cells were then put in block and allowed to
incubate for 24-hours. Following the incubation period, select antibodies (calponin, desmin, smooth
muscle actin, and cytokeratin) were diluted in block according to manufacturer recommendations. The
antibodies were added to the chambers, each row (2 chambers) receiving a different antibody. Following
a second 24-hour incubation period, appropriate secondary antibodies were diluted in block according to
manufacturer recommendations. The secondary antibodies were added to the appropriate chambers and
allowed to incubate for two hours. DAPI diluted in PBS was then added to the chamber, and allowed to
incubate for five minutes. Following incubation, the chambers were removed and the slide was mounted
using a lab made glycerol based solution. Slide were investigated under a microscope and pictures were
acquired using a digital camera and a confocal microscope.

Mesenchymal stem cells may be useful in the treatment of post prostatectomy
stress urinary incontinence by populating sphincteric scar with viable smooth
muscle cells.

Figure 1. Negative and Positive Immunoassay for Smooth Muscle Charactersitics.
The images above were captured by a confocal miscroscope. The blue are DapI stained
nuclei, while the green are FITC marked smooth muscle actin, a characteristic found in
smooth muscle cells. The image on the right shows a colony that did not differentiate,
while the image on the right shows a colony that did.
Figure 2. Calponin in TGFß-3 treated
cells. The image was captured using a
confocal microscope. The blue DapI stains
are the nuclei and the green FITC stain are
antibodies for calponin. The Image above
shows presence of calponin in the treated
cells.
.

Figure 3. Time course of TGFß3 treatment. The boxes represent
the eight chambers of a Lab-Tek
chamber slide. non-treated MSCs
and treat MSCS were placed in
alternating rows. The top half of
the chambers were only treated
for 24-hours while the bottom half
of the chambers were treated for
48-hours. One column was then
stained for calponin while the
other column was stained for
smooth muscle actin.
This second experiment showed that the MSCs that were treated for 48-hours showed
more smooth muscle characteristics than the MSCs that were treated for 24 hours. Due to
an error with DAPI staining, the exact ratio of cells that successfully differentiated to
smooth muscle cells could not be determined, but it appeared that the ratio of
differentiation in the 48-hour treatment is similar to the 72-hour treatment.

RESULTS

CONCLUSIONS

Results:
The following figure
demonstrates the process by
which TGF-ß can stimulate
smooth muscle cell
differentiation. TGF-ß can
both directly stimulate
smooth muscle cell
differentiation and
upregulates the expression if
myocardin which assists in
the differentiation of smooth
muscle cells.

Immunostaining was used to test the presence of smooth muscle differentiation. By observing the
characteristics expressed, one could determine if the mesenchymal stem cells had been differentiated into
smooth muscle cells. An example of immunostains seen in a differentiated colony of smooth muscle cells and
a nondifferentiated colony of smooth muscle cells are shown in figure 1. Following the experiment, TGFß-1
failed to cause smooth muscle differentiation in the mesenchymal stem cell. The TGFß-3 treatment resulted in
a positive differentiation of smooth muscle cells from mesenchymal stem cells. The left image in figure 1
shows the presence of smooth muscle actin in cells treated with TGFß-3. Figure 2 shows the presence of
calponin, another smooth muscle marker, in a different colony of cells treated by TGFß-3. Following the
results, a second experiment was conducted in order to determine the ideal exposure for the treatment of
MSCs with TGFß-3. The methods above were followed until the treatment time for the cells. Half of the
chambers were treated for 24-hours and half the chambers were treated for 48 hours. A representation can be
seen in figure 3.

The study found that while TGFß-1 is not an optimal cytokine to consistently produce
smooth muscle cells, TGFß-3 is. Additionally, it was determined that though the previous
study that used TGFß-3 treated the cells for only 24-hours, it is more optimal to treat the
cells for 48-hours or 72-hours. The next step of the project is to inoculate the smooth
muscles into the urinary incontinent mouse model and see the results.
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